‘Designer Drugs’: A Problem in Clinical Toxicology

Medical Toxicology and Adverse Drug Experience

Volumn 3, Issue 1, 1988, Pages 1-17

  Buchanan, James F ^a   Brown, Christopher R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; FENTANYL DERIVATIVE; MESCALINE DERIVATIVE; METHAMPHETAMINE; METHAQUALONE DERIVATIVE; OPIATE; PETHIDINE DERIVATIVE; PHENCYCLIDINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG;

DRUG ABUSE; DRUG ANALYSIS; DRUG INTOXICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LAW; LEGAL ASPECT; REVIEW;

CHEMISTRY, PHARMACEUTICAL; HUMAN; LEGISLATION, DRUG; STREET DRUGS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023860818     PISSN: 01135244     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/BF03259928     Document Type: Article

References (68)

1. Acute lead poisoning in two users of illicit methamphetamine
2. The isolation and identification of precursors and reaction products in the clandestine manufacture of methaqualone and mecloqualone
3. Amphetamine cardiomyopathy (letter)
4. The bogus drug: three methyl and alpha methyl fentanyl sold as ‘china white’
5. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), seven cases
6. Illegally manufactured 2,5-dimethoxy-4-bromoamphetamine in connection with a fatal intoxication
7. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion
8. China white: the bogus drug
9. Methaqualone RIA structure versus reactivity
10. Phencyclidine (PCP): structure versus reactivity
11. PHP, a new drug of abuse
12. Bromo-DMA: the Australasian hallucinogen?
13. The clinical syndrome of striatal dopamine deficiency, parkinsonism induced by 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)
14. Acute cardiomyopathy secondary to intravenous amphetamine abuse
15. The use of psychostimulants in general psychiatry
16. 3, 4-methylenedioxyamphetamine (MDA): analytical and forensic aspects of fatal poisoning
17. PMA deaths in Ontario
18. Identification of fentanyl derivatives
19. The identification of quinazolinones on the illicit market
20. Pharmacologic investigation of compounds related to 3,4-methylenedioxyamphetamine (MDA)
21. Intracranial hemorrhage with amphetamine use
22. ‘Eve’ and ‘Ecstasy’, a report of fíve deaths associated with the use of MDEA and MDMA
23. The psychological and physiological effects of MDMA on normal volunteers
24. Toxin-induced parkinsonism: recent developments
25. Identification of 3,4 methylenedioxymethamphetamine
26. A case of phenylcyclohexylpyrrolidine (PHP) intoxication treated with physostigmine
27. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure, a syndrome resembling heatstroke
28. Subjective reports of the effects of MDMA in a clinical setting
29. Can drugs be used to enhance the psychotherapeutic process?
30. MDMA: the dark side of ecstasy
31. Death in amphetamine users: causes and rates
32. Chemical synthesis and molecular pharmacology of hydroxylated 1-(1-phenylcyclohexyl)piperadine derivatives
33. Rhabdomyolysis and shock after intravenous amphetamine administration
34. Fatal methamphetamine poisoning associated with hyperpyrexia
35. Behind the identification of china white
36. MPTP and Parkinson’s disease
37. Parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of parkinson’s disease
38. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
39. + ): identification of a metabolite of MPTP, a toxin selective to the substantia nigra
40. 3,4-methylenedioxyamphetamine overdose
41. Effects of hallucinogenic drugs on serotonergic neuronal systems
42. Determination of 1-(1-phenylcyclohexylpyrrolidine (PHP) in postmortem specimens: a case report
43. More than medical significance: LSD and American psychiatry 1953 to 1966
44. Structure-activity relationships of phenethylamine hallucinogens
45. Synthesis, identification and acute toxicity of alpha-benzylphenethylamine and alpha-benzyl-N-methylphenethylamine: contaminants in clandestine preparation of amphetamine and methamphetamine
46. Environmental and drug-induced hyperthermia: pathophysiology, recognition, and management
47. 4-Bromo-2,5-dimethoxyphenethylamine: identification of a new street drug
48. A fatal case involving methylenedioxyamphetamine
49. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals
50. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analog
51. Effects of cycloalkyl ring analogs of phencyclidine on behavior in rodents
52. Chemistry of phenethylamines related to mescaline
53. Profiles of psychedelic drugs: DOB
54. Profiles of psychedelic drugs: STP
55. Profiles of psychedelic drugs: TMA-2
56. The background and chemistry of MDMA
57. Potential misrepresentation of 3, 4-methylenedioxyamphetamine (MDA): a toxicologic warning
58. Illicit synthesis of phencyclidine (PCP) and several of its analogs
59. Animal pharmacology and human pharmacology of 3-methoxy-4,5-methylenedioxyisopropylamine (MMDA)
60. MDMA, nonmedical use and intoxication
61. Methylenedioxyamphetamine: clinical description of overdose, death and review of pharmacology
62. 2,5-Dimethoxy-4-methylamphetamine (STP): a new hallucinogenic drug
63. Identification of a new phencyclidine analog, l-(l-phenylcyclohexyl)-4-methylpiperidine, as a drug of abuse
64. Phencyclidine contaminant generates cyanide
65. Synthesis of methaqualone and its diphasic titration in pure and tablet forms
66. Intellectual changes in patients with MPTPinduced parkinsonism
67. A death due to 4-bromo-2, 5-dimethoxyamphetamine